Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study.

Elens, Laure;Becker, Matthijs L;Haufroid, Vincent;Hofman, Albert;van Schaik, Ron H N;et.al.
(2011) Pharmacogenetics and Genomics — Vol. 21, n° 12, p. 861-866 (2011)

Files

No attached file found for this publication.

Details

Authors
Show more
Abstract
CYP3A4 is involved in the oxidative metabolism of many drugs and xenobiotics including the HMG-CoA reductase inhibitor simvastatin. The objective of this study was to investigate whether a new CYP3A4 functional single nucleotide polymorphism (SNP) in intron 6 (CYP3A4*22) modifies the effect of simvastatin on total cholesterol (TOTc) or LDL cholesterol (LDLc) reduction in a population-based cohort study.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Elens, L., Becker, M. L., Haufroid, V., Hofman, A., Visser, L. E., Uitterlinden, A. G., Stricker, B. C., & van Schaik, R. H. N. (2011). Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study. Pharmacogenetics and Genomics, 21(12), 861-866. https://doi.org/10.1097/FPC.0b013e32834c6edb (Original work published 2011)